###begin article-title 0
VHL Type 2B Mutations Retain VBC Complex Form and Function
###end article-title 0
###begin p 1
Conceived and designed the experiments: KEH CML WKR. Performed the experiments: KEH CML. Analyzed the data: KEH CML WKR. Contributed reagents/materials/analysis tools: WKR. Wrote the paper: KEH WKR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 171 174 171 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
von Hippel-Lindau disease is characterized by a spectrum of hypervascular tumors, including renal cell carcinoma, hemangioblastoma, and pheochromocytoma, which occur with VHL genotype-specific differences in penetrance. VHL loss causes a failure to regulate the hypoxia inducible factors (HIF-1alpha and HIF-2alpha), resulting in accumulation of both factors to high levels. Although HIF dysregulation is critical to VHL disease-associated renal tumorigenesis, increasing evidence points toward gradations of HIF dysregulation contributing to the degree of predisposition to renal cell carcinoma and other manifestations of the disease.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 60 63 60 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
This investigation examined the ability of disease-specific VHL missense mutations to support the assembly of the VBC complex and to promote the ubiquitylation of HIF. Our interaction analysis supported previous observations that VHL Type 2B mutations disrupt the interaction between pVHL and Elongin C but maintain partial regulation of HIF. We additionally demonstrated that Type 2B mutant pVHL forms a remnant VBC complex containing the active members ROC1 and Cullin-2 which retains the ability to ubiquitylate HIF-1alpha.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Our results suggest that subtypes of VHL mutations support an intermediate level of HIF regulation via a remnant VBC complex. These findings provide a mechanism for the graded HIF dysregulation and genetic predisposition for cancer development in VHL disease.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell1">[1]</xref>
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell1">[1]</xref>
###xml 488 491 488 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 511 514 511 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Crossey1">[2]</xref>
###xml 515 518 515 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Chen1">[4]</xref>
###xml 909 912 909 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Ritter1">[5]</xref>
###xml 960 963 960 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1086 1089 1086 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Ang1">[6]</xref>
###xml 1091 1094 1091 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Pastore1">[7]</xref>
###xml 1203 1206 1203 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Nickerson1">[8]</xref>
###xml 1360 1363 1360 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell1">[1]</xref>
###xml 1365 1368 1365 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Banks1">[9]</xref>
###xml 1370 1374 1370 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell2">[10]</xref>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 914 922 <span type="species:ncbi:9606">Patients</span>
###xml 1351 1359 <span type="species:ncbi:9606">patients</span>
von Hippel-Lindau (VHL) disease is an autosomal dominant familial cancer syndrome caused by germline mutation or loss of the VHL tumor suppressor gene that affects approximately 1 in 36,000 individuals [1]. Individuals with VHL disease develop an array of tumors, including clear cell renal cell carcinomas (ccRCC), cerebellar and retinal hemangioblastomas, and pheochromocytomas [1]. VHL disease is divided by genotype into subtypes which predict the spectrum of risk for development of VHL-associated lesions [2]-[4]. Type 1 VHL disease predisposes to the development of ccRCC and hemangioblastoma. All patients with Type 2 VHL disease are at risk for pheochromocytoma. Type 2A VHL disease is further characterized by high risk for hemangioblastoma, and Type 2B VHL disease is associated with high risk for both hemangioblastoma and RCC. Type 2C VHL disease individuals exclusively develop pheochromocytoma [5]. Patients homozygous for the Arg200Trp (R200W) VHL mutation, located in the extreme C-terminal domain of the 213 amino acid VHL protein (pVHL), develop Chuvash Polycythemia [6], [7]. Biallelic inactivation of pVHL has also been reported in upwards of 90% of individuals with sporadic ccRCC [8]. Thus, a thorough understanding of wild-type and disease-associated mutant pVHL activities has potential to impact a broad spectrum of affected patients [1], [9], [10].
###end p 9
###begin p 10
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Passmore1">[11]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Megumi1">[12]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Pause1">[13]</xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Stebbins1">[15]</xref>
###xml 821 825 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Passmore1">[11]</xref>
###xml 932 936 932 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Megumi1">[12]</xref>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Kamura1">[14]</xref>
###xml 507 512 <span type="species:ncbi:9606">Human</span>
The VHL protein acts as the substrate recognition subunit of an E3 ubiquitin ligase complex analogous in structure to the SCF complex. The SCF and SCF-like complexes typically contain four subunits, including a RING finger protein (ROC1/Rbx1), a cullin protein (CUL/Cul), and two adaptor proteins linking the cullin to the substrate binding protein [11]. In the pVHL E3 complex (VBC), pVHL acts as the substrate binding protein and is responsible for the specificity of the complex-target interaction [12]. Human pVHL directly interacts with Elongin C, while Elongin B links pVHL-Elongin C to cullin 2 (CUL2)-ROC1 [13]-[15]. The VBC complex serves as a platform through which the E2 ubiquitin-conjugating enzyme, bound by CUL2-ROC1, and the pVHL-bound substrate are brought into proper positioning for ubiquitin transfer [11]. In the VBC complex, ROC1 functions to recruit the E2 enzyme and also promotes internal complex stability [12], [14].
###end p 10
###begin p 11
###xml 297 301 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Iliopoulos1">[16]</xref>
###xml 302 306 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Li1">[21]</xref>
The primary targets of the VBC complex are the hypoxia inducible factors, HIF-1alpha and HIF-2alpha. The HIF factors direct the transcriptional response to hypoxia by activating the expression of genes involved in angiogenesis, cell proliferation, erythropoiesis, energy metabolism, and apoptosis [16]-[21].
###end p 11
###begin p 12
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Kondo1">[22]</xref>
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Hoffman1">[23]</xref>
###xml 375 378 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Li1">[21]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Knauth1">[24]</xref>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Clifford1">[20]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Li1">[21]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Hoffman1">[23]</xref>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 851 854 851 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 963 966 963 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Loss of the pVHL tumor suppressor, as occurs with Type 1 VHL mutations, is believed to promote renal tumorigenesis primarily through loss of pVHL-mediated HIF regulation [22]. Correspondingly, Type 2C VHL missense mutations display fully intact regulation of HIF factors, consistent with the lack of conveyed risk for RCC development [23]. In the case of Type 2A and Type 2B VHL missense mutations, titrated degrees of HIF regulation appear to correlate with the subtype-specific risk of ccRCC [21], [24]. While the differing capabilities of VHL disease-associated mutants to regulate HIF have been explored [20], [21], [23]-[25], the mechanism of retained HIF regulation and the link between differing levels of HIF regulation and the clinical spectrum observed in VHL disease is not yet fully understood. In this study, we re-examined the effect of VHL missense mutations to disrupt the formation of the VBC complex, and demonstrate that characteristic Type 2B VHL mutations form a low-abundance VBC complex which retains the ability to ubiquitylate HIF-1alpha.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Cell Lines
###end title 14
###begin p 15
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vhl</italic>
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 328 331 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Hansen1">[26]</xref>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vhl</italic>
###xml 1182 1183 1176 1177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 467 473 <span type="species:ncbi:10090">murine</span>
###xml 667 673 <span type="species:ncbi:9913">bovine</span>
Vhl-null embryonic stem (ES) cells or VHL-deficient 786-0 RCC cells were transfected with vectors specifying human wild-type VHL or representative VHL mutants Y112H (Type 2A), R167Q (Type 2B), L188V (Type 2C), or R200W (Chuvash polycythemia) using vectors and techniques as previously described [25]. 786-0 cells expressing the VHL mutant D121G (Type 2B), generated as previously described [26], were generously provided by Dr. William Kim, Chapel Hill, NC. Vhl-null murine ES cells and transfected derivatives were maintained in culture media comprised of Dulbecco's Modified Eagle Medium (DMEM, various manufacturers), supplemented with 10% ES cell-certified fetal bovine serum (Invitrogen, Carlsbad, CA), non-essential amino acids, L-glutamine, 2-mercaptoethanol, and leukemia inhibitory factor, and were grown on gelatin-coated plates in the absence of feeder cells. Renal cell carcinoma 786-0 cells were acquired from the American Type Culture Collection (Manassas, VA). 786-0 cells and transfected derivatives were maintained in DMEM, supplemented with 10% FBS, non-essential amino acids, L-glutamine, and 2-mercaptoethanol. All cultures were maintained at 37degreesC in 5% CO2. For hypoxia mimetic experiments, cells in log-phase growth were placed in media supplemented with 100 mM cobalt chloride (Sigma, St. Louis, MO) or fresh unsupplemented media.
###end p 15
###begin title 16
Immunoblot Analysis
###end title 16
###begin p 17
###xml 682 688 <span type="species:ncbi:9986">rabbit</span>
###xml 752 757 <span type="species:ncbi:10090">mouse</span>
###xml 805 811 <span type="species:ncbi:9986">rabbit</span>
###xml 862 868 <span type="species:ncbi:9986">rabbit</span>
###xml 914 918 <span type="species:ncbi:9925">goat</span>
###xml 991 997 <span type="species:ncbi:9986">rabbit</span>
###xml 1055 1060 <span type="species:ncbi:10090">mouse</span>
###xml 1130 1135 <span type="species:ncbi:10090">mouse</span>
###xml 1213 1219 <span type="species:ncbi:9986">rabbit</span>
###xml 1306 1311 <span type="species:ncbi:10090">mouse</span>
###xml 1318 1324 <span type="species:ncbi:9986">rabbit</span>
###xml 1335 1339 <span type="species:ncbi:9925">goat</span>
###xml 1358 1369 <span type="species:ncbi:3704">horseradish</span>
Cells were lysed in Mammalian Protein Extraction Reagent (M-PER; Pierce Biotechnology, Rockford, IL) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche, Basel, Switzerland). The Bradford Quantification Method (Amresco, Solon, OH) was used to determine protein concentration. Cell lysates were resolved by SDS-PAGE and subsequently transferred to Hybond ECL nitrocellulose membrane (GE Healthcare, United Kingdom). Immediately following transfer, membranes were stained with Ponceau S to confirm even transfer, blocked in 5% nonfat dry milk diluted in phosphate-buffered saline containing 0.1% Tween-20 (PBS-T), and then probed with the following primary antibodies: rabbit polyclonal anti-HA tag (Abcam, Cambridge, MA: ab9110, 1:1000), mouse monoclonal anti-pVHL (Abcam, ab11189, 1:2000), rabbit polyclonal anti-cullin-2 (Abcam: ab1870, 1:1000), rabbit polyclonal anti-ROC1 (Abcam: ab2977, 1:500), goat polyclonal anti-Elongin C (Santa Cruz, Santa Cruz, CA: sc-1559, 1:200), rabbit polyclonal anti-Elongin B (Santa Cruz: sc-11447, 1:200), mouse monoclonal anti-Myc tag (Cell Signaling, Danvers, MA: 9B11, 1:1000), mouse monoclonal anti-HIF-2alpha (GeneTex, San Antonio, TX: GTX30123, 1:1000), and rabbit polyclonal anti-Ku80 (GeneTex: GTX70485, 1:2000). Secondary antibodies used were anti-mouse, anti-rabbit, and anti-goat IgG conjugated to horseradish peroxidase (various manufacturers) and detected with the ECL Plus Western Blotting System (GE Healthcare) using exposure to BlueLite autoradiography film (ISC BioExpress, Kaysville, UT) and processing via a Kodak RP X-OMAT Processor (Rochester, NY).
###end p 17
###begin title 18
Immunoprecipitation Analysis
###end title 18
###begin p 19
M-PER cell lysates were subjected to immunoprecipitation (IP) using either the Profound Mammalian HA Tag IP/Co IP Kit or the Profound Mammalian Myc Tag IP/Co IP Kit, as per manufacturer's specifications (Pierce Biotechnology). For the reverse co-IP analysis, stably-transfected 786-0 cell lines were transiently transfected with a plasmid encoding myc-tagged cullin-2, a generous gift from Dr. Y. Xiong, Chapel Hill, NC, using Solution V of the Amaxa Tranfection System (Amaxa, Gaithersberg, MD). Twenty hours post-transfection, transfected cells were incubated in media supplemented with 5 microM MG-132 (Calbiochem, Gibbstown, NJ) proteasome inhibitor or fresh unsupplemented media for four hours, followed by protein extraction with M-PER and IP analysis as above.
###end p 19
###begin title 20
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro HIF-1alpha Ubiquitylation Assay
###end title 20
###begin p 21
###xml 3 11 3 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Cockman1">[18]</xref>
###xml 291 292 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1015 1016 981 982 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1231 1236 <span type="species:ncbi:4565">Wheat</span>
###xml 1328 1333 <span type="species:ncbi:9606">human</span>
An in vitro ubiquitylation assay was adapted from the protocol developed by Cockman et al. [18]. 786-0 cell lines incubated for four hours in 5 microM MG-132 were washed and collected in PBS. The cells were then washed twice in Ub Extraction Buffer (20 mM Tris, pH 7.5, 5 mM Kcl, 1.5 mM MgCl2, 1 mM DTT) and disrupted using a dounce homogenizer. The cell lysates were centrifuged at 10,000xg for 10 minutes at 4degreesC. Each reaction was set up in a total volume of 40 microL, containing 23 microL cell extract, 5 microL HIF1alpha-myc substrate, and 12 microL reaction solution. The "reaction solution" was composed of ATP Regenerating System (20 mM Tris, pH 7.5, 10 mM ATP (GE Healthcare)), 10 mM magnesium acetate (Promega Corporation, Madison, WI), 300 mM creatine phosphate, 0.5 mg/mL creatine phosphokinase (MP Biomedicals, LLC, Irvine, California), 20 microg ubiquitin, and 150 uM ubiquitin aldehyde (Biomol International, Plymouth Meeting, PA). When reactions excluded a specific component, nuclease-free dH2O was substituted to maintain the total reaction volume. Reactions were incubated at 30degreesC for 270 minutes and then subjected to immunoblot analysis. HIF1alpha-myc substrate was produced through TNT(R) coupled Wheat Germ Extract Systems (Promega, Madison, WI) from a plasmid encoding full-length functional human HIF1alpha-myc protein, a generous gift from Dr. M. C. Simon, Philadelphia, PA.
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Type 2B mutant pVHL proteins promote incomplete normoxic HIF-2alpha stabilization
###end title 23
###begin p 24
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 156 159 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vhl</italic>
###xml 198 202 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 433 436 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 557 566 549 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g001">Figure 1A</xref>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 165 171 <span type="species:ncbi:10090">murine</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
We have previously shown that human VHL mutations representative of Types 2A and 2B VHL disease impart an intermediate degree of HIF-2alpha regulation in a Vhl-null murine ES cell expression system [25]. In order to evaluate this trend in human RCC cells, 786-0 RCC-derived cells, known to lack pVHL expression and over-express HIF-2alpha, were reconstituted with expression vectors encoding wild-type or VHL disease-specific mutant VHL cDNA. Individual clones expressing mutant pVHL comparable to wild-type levels were selected for subsequent experiments. Figure 1A depicts a representative immunoblot for the expression of wild-type as well as RCC-associated Type 2A (Y112H) and 2B (R167Q) mutant HA-tagged pVHL in 786-0 RCC clones.
###end p 24
###begin title 25
VHL disease associated mutations demonstrate a graded amount of HIF Regulation.
###end title 25
###begin p 26
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 397 400 393 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 531 532 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 269 274 <span type="species:ncbi:9606">human</span>
A. Anti-HA immunoblot for expression of HA-tagged human pVHL in transgenic 786-0 clones. Whole-cell protein extracts were prepared from 786-0 clones deficient for VHL expression (Vector) or modestly expressing wild-type (WT) or missense (Y112H, R167Q) mutant HA-tagged human pVHL. B. Anti-HIF-2alpha immunoblot for HIF stabilization in 786-0 clones. Whole-cell protein extracts were prepared from VHL-deficient 786-0 cells or WT or mutant HA-pVHL-rescued 786-0 cells incubated in the presence or absence of the hypoxia mimetic CoCl2 for 24 hours. Ku80 immunoblot was used as a control for equal loading.
###end p 26
###begin p 27
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 344 331 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g001">Figure 1B</xref>
###xml 347 350 343 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 588 589 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 623 626 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 769 773 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Stebbins1">[15]</xref>
###xml 783 786 767 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 910 911 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To study the ability of RCC-associated mutant pVHL to regulate HIF in 786-0 cells, the hypoxia mimetic cobalt chloride (CoCl2) was used to simulate hypoxic conditions. Cells were placed in either standard growth media or media supplemented with 100 mM CoCl2for 24 hours followed by analysis of HIF-2alpha protein levels by immunoblot (Figure 1B). VHL-null vector-only transfected cells (vector) failed to suppress HIF-2alpha under standard conditions and lacked further induction under simulated hypoxic conditions. Introduction of wild-type HA-pVHL restored normoxic suppression and CoCl2 induction of HIF-2alpha. Type 2A VHL mutant Y112H cells failed to completely suppress HIF-2alpha levels, as expected due to the predicted disruption of the HIF interaction domain [15]. Type 2B VHL mutant R167Q cells displayed partial suppression of HIF-2alpha while retaining HIF-2alpha stabilization in response to CoCl2. These observations were confirmed in multiple independently-derived 786-0 clones (data not shown).
###end p 27
###begin title 28
Type 2B mutant protein participates in a VBC complex containing Cullin2
###end title 28
###begin p 29
###xml 501 505 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Pause1">[13]</xref>
###xml 507 511 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Duan1">[27]</xref>
###xml 512 516 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Ohh1">[30]</xref>
###xml 633 637 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 321 327 <span type="species:ncbi:10090">murine</span>
###xml 611 617 <span type="species:ncbi:10090">murine</span>
To determine the correspondence between the observed partial retention of HIF-2alpha regulation and formation of a competent VBC complex, we analyzed the interaction of wild-type and disease-specific mutant HA-pVHL with known components of the VBC complex by co-IP and reverse co-IP studies in transgenic human 786-0 and murine ES cells. Based on prevailing models, Type 2B mutant pVHL proteins, including R167Q, are predicted to disrupt VBC complex formation by eliminating Elongin C binding to pVHL [13], [27]-[30]. We have previously observed the inability of R167Q HA-pVHL to bind Elongin C in a transgenic murine ES cell system [25].
###end p 29
###begin p 30
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vhl</italic>
###xml 283 292 283 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figure 2A</xref>
###xml 453 462 453 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figure 2A</xref>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Clifford1">[20]</xref>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 1133 1136 1133 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 102 108 <span type="species:ncbi:10090">murine</span>
###xml 916 922 <span type="species:ncbi:10090">murine</span>
VBC complex formation was assessed by co-IP analysis of proteins interacting with HA-pVHL in Vhl-null murine ES cells expressing wild-type pVHL (WT), mutants Y112H, R167Q, L188V, and R200W, or no transgene (-/-). HA-pVHL pull-down was confirmed in each IP by anti-HA immunoblot (HA, Figure 2A). Each HA-pVHL-containing complex was then individually tested for interaction with known members of the VBC complex through protein-specific co-IP immunoblot (Figure 2A). As expected based on both previous reports and the localization of the respective mutations [20], [25], the R167Q HA-pVHL failed to substantially co-immunoprecipitate Elongin C, whereas wild-type HA-pVHL and mutant HA-pVHL representing Y112H, L188V, and R200W retained this interaction. Furthermore, wild-type HA-pVHL and mutant HA-pVHL representing Y112H, L188V, and R200W demonstrated interaction with complete VBC complex detecting the presence of murine Elongin B, Cul2, and Rbx1. Elongin B, Cul2, and Rbx1 also clearly associated with the R167Q HA-pVHL, suggesting that the VBC complex is at least partially intact in cells expressing this representative Type 2B VHL mutation.
###end p 30
###begin title 31
Co-immunoprecipitation of VBC complex proteins with type 2B mutant pVHL.
###end title 31
###begin p 32
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vhl<sup>&#8722;/&#8722;</sup></italic>
###xml 268 274 <span type="species:ncbi:10090">murine</span>
A. Anti-HA immunoprecipitation of HA-pVHL and associated VBC complex members in transgenic ES cell clones. Anti-HA IP products were probed for successful pull-down of WT or mutant HA-pVHL and for co-IP of the indicated VBC complex members in stably-transfected Vhl-/- murine ES cells. B. and C. Anti-HA immunoprecipitation of HA-pVHL from transgenic 786-0 clones. Anti-HA IP products were probed for successful pull-down of WT or mutant HA-pVHL by anti-pVHL (B) or anti-HA (C) immunoblot and for co-IP of the indicated VBC complex members in stably-transfected 786-0 cells.
###end p 32
###begin p 33
###xml 175 178 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 292 295 292 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 629 638 629 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figure 2B</xref>
###xml 652 661 652 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figure 2C</xref>
###xml 764 781 764 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figures 2B and 2C</xref>
###xml 84 90 <span type="species:ncbi:10090">murine</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 1314 1319 <span type="species:ncbi:9606">human</span>
In order to discern if the observed remnant VBC complex in R167Q HA-pVHL-expressing murine ES cells was an artifact of human-mouse interactions, we examined the same panel of VHL mutations for VBC complex formation in stably-transfected human 786-0 RCC cells. A second representative Type 2B VHL mutation D121G was included in this analysis to determine whether the formation of a remnant complex is limited to the specific Type 2B mutant R167Q HA-pVHL or is more broadly relevant to Type 2B VHL disease. Again, pVHL-associated proteins were co-immunoprecipitated, and pull-down of HA-pVHL was confirmed for each IP by anti-VHL (Figure 2B) or anti-HA (Figure 2C) immunoblot, followed by detection of known VBC complex members by protein-specific co-IP immunoblot (Figures 2B and 2C). Both R167Q and D121G mutant HA-pVHL failed to demonstrate a strong interaction with Elongin C, although robust association was detected for wild-type and the other mutant HA-pVHL proteins. The remaining VBC complex members were again associated with wild-type and all of the HA-pVHL mutants tested, including the Type 2B mutants R167Q and D121G. This experiment suggests that both of the Type 2B mutant HA-pVHL proteins studied may retain at least partial interaction with Elongin C and recruit a complex containing the essential human VBC E3 ubiquitin ligase components CUL2 and ROC1.
###end p 33
###begin p 34
###xml 228 236 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g003">Figure 3</xref>
###xml 415 426 415 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g002">Figure 2B&#8211;C</xref>
To confirm the observed interaction between R167Q HA-pVHL and CUL2, a myc-tagged CUL2 protein was transiently expressed in stable 786-0 cell lines expressing wild-type or RCC-associated mutant HA-pVHL for reverse co-IP studies (Figure 3). Cell extracts were subjected to anti-myc-agarose IP, and pull-down of myc-CUL2 was confirmed by anti-CUL2 immunoblot. Anti-HA co-IP immunoblot verified the results depicted in Figure 2B-C, displaying myc-CUL2 interaction with wild-type, Y112H, and R167Q HA-pVHL.
###end p 34
###begin title 35
Reverse co-immunoprecipitation confirms CUL2-pVHL protein interaction in R167Q mutation.
###end title 35
###begin p 36
Anti-myc immunoprecipitation of myc-CUL2 and associated HA-pVHL in 786-0 clones. Stable 786-0 clones expressing vector-only (ST) or WT or mutant HA-pVHL were transiently transfected with wild-type myc-tagged CUL2 and subjected to myc-IP. Upper panel, IP of Myc-tagged Cul2 detected by anti-CUL2 immunoblot. Lower panel, co-IP of WT and mutant HA-pVHL detected by anti-HA immunoblot.
###end p 36
###begin title 37
Type 2B mutant pVHL retains HIF-1alpha-ubiquitylating activity
###end title 37
###begin p 38
###xml 211 219 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 247 253 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 253 257 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Cockman1">[18]</xref>
###xml 523 527 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Clifford1">[20]</xref>
###xml 680 688 660 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
To determine if the remnant R167Q HA-pVHL-CUL2 complex retained E3 ubiquitin ligase activity, wild-type and mutant HA-pVHL were analyzed for competence to ubiquitinate HIF-1alpha using a modified version of the in vitro assay developed by Cockman et al.[18]. Exogenous HIF-1alpha was used as the ubiquitylation target in this experiment as the 786-0 parental cell line lacks confounding endogenous HIF-1alpha expression. The R167Q and a second Type 2B mutation (Q195X) have been shown to retain interaction with HIF-1alpha [20]. Retention of E3 ligase activity by the remnant R167Q mutant pVHL-CUL2 VBC complex, therefore, should correspond to preserved HIF-1alpha ubiquitylation in vitro.
###end p 38
###begin p 39
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 122 130 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 240 248 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003801-g004">Figure 4</xref>
###xml 1378 1383 1330 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1385 1389 1337 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Cockman1">[18]</xref>
###xml 1599 1607 1543 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 60 65 <span type="species:ncbi:9606">human</span>
In vitro-transcribed (TNT) myc-tagged full-length wild type human HIF-1alpha (HIF-1alpha-myc) was subjected to a modified in vitro ubiquitylation assay, using anti-myc immunoblot to visualize ubiquitylation of the HIF-1alpha-myc substrate (Figure 4, components of each analysis indicated above lane). The HIF-1alpha-myc protein migration for each cell line is summarized by a shaded line to the right of the immunoblot. TNT HIF-1alpha-myc substrate in the absence of reaction solution or cell extract served as a negative control for the unmodified electrophoretic mobility of the HIF-1alpha-myc protein. For each cell line in our assay, further controls were provided by excluding cell extract (first reaction) or TNT HIF-1alpha-myc substrate (second reaction). The third reaction for each cell line contained all three necessary components for the ubiquitylation reaction. An upward shift in HIF1alpha-myc mobility, as exemplified by the wild-type (WT) complete reaction, indicates HIF-1alpha-myc poly-ubiquitylation. The HIF-1alpha-myc protein was shifted only slightly upwards in the reaction utilizing extract from control vector-only 786-0 cells, demonstrating the basal pVHL-independent HIF-1alpha ubiquitylation present in this system. Type 2A Y112H mutant HA-pVHL failed to promote HIF-1alpha-myc mobility shift beyond basal levels, confirming previous work by Cockman et al. [18]. Notably, Type 2B R167Q mutant HA-pVHL promoted HIF-1alpha-myc mobility shift similar to WT HA-pVHL, demonstrating that the remnant R167Q HA-pVHL-Cullin-2 complex retains E3 ligase activity towards HIF-1alpha in vitro.
###end p 39
###begin title 40
pVHL-dependent HIF-1alpha ubiquitylation in 786-0 cell lines.
###end title 40
###begin p 41
###xml 74 82 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Anti-myc immunoblot to visualize migration shift of myc-tagged HIF-1alpha in vitro. Cell extracts from 786-0 clones expressing vector alone or WT or mutant HA-pVHL were incubated in the presence or absence of ubiquitylation reaction solution and TNT HIF-1alpha-myc and subjected to anti-myc immunoblot. A band representing unmodified TNT HIF-1alpha-myc, as depicted in the TNT lane, runs just below the ladder marker at 113.9 kDa. Upward shift of myc-HIF-1alpha, as seen in complete reaction lanes for WT and R167Q, indicates poly-ubiquitylation. The TNT HIF-1alpha-myc migration pattern for each complete reaction lane is graphically summarized to the right of the immunoblot.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 763 767 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
###xml 769 777 765 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 826 829 822 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 962 966 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Knauth1">[24]</xref>
###xml 1087 1090 1079 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1155 1159 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Li1">[21]</xref>
In addition to the strong association of sporadic ccRCC with biallelic VHL inactivation and of VHL disease-associated ccRCC with subtype-specific germline VHL mutations, evidence from xenograft models of tumor growth strongly supports the requirement for pVHL-mediated HIF regulation in suppression of renal tumorigenesis. However, several lines of evidence suggest that dose-dependent effects on basal HIF levels influence VHL-associated tumor development and behavior. Our prior investigation in eupoloid primary ES cell lines, utilized as a strategy to avoid interference from transforming cancer cell events, demonstrated a bias toward HIF-2alpha dysregulation for VHL Type 2B mutation, and a graduated degree of HIF dysregulation across the disease subtypes [25]. In vitro studies of RCC-predisposing Type 2A and Type 2B VHL missense mutations have revealed a correlation between the degree of mutant pVHL-mediated HIF-alpha dysregulation and risk of ccRCC [24]. In a recent study performed in both 786-0 and a second RCC-derived cell line, RCC4, representative Type 2A and Type 2B VHL mutations demonstrated intermediate levels of HIF stabilization [21]. Taken together, these results suggest that Type 2A and Type 2B mutant pVHL proteins retain an intermediate degree of HIF regulation, rather than an "all-or-none" pattern of regulation, likely contributing to the distinct phenotypes observed in these VHL disease subtypes.
###end p 43
###begin p 44
###xml 594 598 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Pause1">[13]</xref>
###xml 600 604 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Duan1">[27]</xref>
###xml 605 609 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Ohh1">[30]</xref>
In this study, we observed intermediate HIF regulatory activity by Type 2A Y112H and Type 2B R167Q mutant HA-pVHL, which could underlie the distinct genotype-phenotype correlations and may provide insight into the biology of sporadic RCC as well. In previous reports of VBC complex formation, the ability of disease-specific mutant pVHL to bind Elongin C was used as a proxy for ability to recruit the remainder of the VBC complex. The absence of 2B mutant HA-pVHL interaction with Elongin C in co-IP studies led to conclusions that alpha-domain mutations in pVHL abolish VBC complex formation [13], [27]-[30]. We report here, however, that both R167Q and D121G Type 2B mutant HA-pVHL participate in a complex with CUL2, ROC1, and Elongin B, as well as potentially with Elongin C either transiently or with greatly reduced abundance.
###end p 44
###begin p 45
###xml 532 536 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Stebbins1">[15]</xref>
The co-immunoprecipitation of VBC complex members with R167Q and D121G mutant HA-pVHL could be due to reduced or transient formation of a wild-type VBC complex and/or formation of an alternate pVHL-Cullin-2 complex with ubiquitin ligase activity. The low abundance of Elongins C and B in association with both representative Type 2B mutant pVHL proteins may represent a limited quantity of stable complete VBC complex. Existing crystal structures depict the pVHL alpha-domain interacting with the VBC complex only through Elongin C [15]. However, the relatively abundant CUL2 and ROC1 in the mutant 2B VBC complex could point to a direct interaction between mutant HA-pVHL and CUL2 or the replacement of Elongins C and B with alternate adaptors linking the mutant HA-pVHL to CUL2-ROC1. Silver stain and proteomic analysis of our Type 2B mutant HA-pVHL immunoprecipitates failed to detect additional bands that could function as replacement adaptors in an alternate HA-pVHL-CUL2 complex (data not shown).
###end p 45
###begin p 46
###xml 91 95 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Clifford1">[20]</xref>
###xml 385 393 373 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 467 471 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Megumi1">[12]</xref>
###xml 681 689 669 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 689 693 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Knauth1">[24]</xref>
The Type 2B mutation R167Q has been shown to permit interaction between pVHL and HIF-alpha [20]. Therefore, if able to recruit an active complete or alternate VBC complex, Type 2B pVHL should be able to direct HIF-alpha ubiquitylation. Indeed, we observed that R167Q mutant HA-pVHL existed in complex with CUL 2 and ROC1 and mediated wild-type levels of HIF-1alpha poly-ubiquitylation in vitro. Though the presence of ROC1 has been shown to stabilize the VBC complex [12], our results cannot discern whether endogenous levels of Type 2B mutant pVHL expression support formation of a stable or transient complex with CUL2. R167Q mutant pVHL has been shown to be relatively unstable in vitro[24], and subtype-specific clinical manifestations of VHL disease may derive from a combination of mutant pVHL stability and the stability and activity of the mutant VBC complex.
###end p 46
###begin p 47
###xml 381 389 373 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 458 461 450 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 643 646 631 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 754 757 738 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 768 772 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Li1">[21]</xref>
###xml 774 778 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003801-Rathmell3">[25]</xref>
In summary, we have demonstrated that disease-associated mutant pVHL proteins retain endogenous HIF-2alpha regulation. Two representative Type 2B mutant pVHL proteins partially preserved interaction with VBC complex members despite reduced binding to Elongin C, and the Type 2B mutant R167Q pVHL retained wild-type levels of ubiquitin ligase activity towards its target HIF-1alpha in vitro. Taken together, our results show that at least a subset of Type 2B VHL missense mutations result in a partial or unstable but active VBC complex which retains the ability to regulate HIF-alpha levels. Furthermore, our results support observations that VHL missense mutations generally confer lower levels of HIF-alpha stabilization than null or truncating Type 1 VHL mutations [21], [25] and provide mechanistic insight into this retained ubiquitin ligase activity.
###end p 47
###begin p 48
The authors would like to acknowledge William Y. Kim, Yue Xiong, and Ian Davis for many helpful discussions.
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
VHL: oxygen sensing and vasculogenesis.
###end article-title 50
###begin article-title 51
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.
###end article-title 51
###begin article-title 52
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.
###end article-title 52
###begin article-title 53
Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.
###end article-title 53
###begin article-title 54
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.
###end article-title 54
###begin article-title 55
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
###end article-title 55
###begin article-title 56
Mutations in the VHL gene in sporadic apparently congenital polycythemia.
###end article-title 56
###begin article-title 57
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
###end article-title 57
###begin article-title 58
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
###end article-title 58
###begin article-title 59
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis, and treatment.
###end article-title 59
###begin article-title 60
Getting into position: the catalytic mechanisms and protein ubiquitylation.
###end article-title 60
###begin article-title 61
Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex.
###end article-title 61
###begin article-title 62
###xml 80 85 <span type="species:ncbi:9606">human</span>
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
###end article-title 62
###begin article-title 63
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
###end article-title 63
###begin article-title 64
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.
###end article-title 64
###begin article-title 65
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
###end article-title 65
###begin article-title 66
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
###end article-title 66
###begin article-title 67
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
###end article-title 67
###begin article-title 68
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
###end article-title 68
###begin article-title 69
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
###end article-title 69
###begin article-title 70
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
###end article-title 70
###begin article-title 71
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
###end article-title 71
###begin article-title 72
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
###end article-title 72
###begin article-title 73
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
###end article-title 73
###begin article-title 74
In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
###end article-title 74
###begin article-title 75
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
###end article-title 75
###begin article-title 76
Inhibition of transcription elongation by the VHL tumor suppressor protein.
###end article-title 76
###begin article-title 77
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
###end article-title 77
###begin article-title 78
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
###end article-title 78
###begin article-title 79
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
###end article-title 79
###begin p 80
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 80
###begin p 81
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work has been supported by F30 ES015248 (CML), R01 CA121781 (WKR, KEH), K08 CA098410 (WKR), and the VHL Family Alliance (WKR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 81

